Phase 4 Heart Disease Trial, Recruiting NCT05262803 Sponsor: Rikke Sorensen Condition: Heart Disease
Back to Heart Disease

Phase 4 Heart Disease Trial, Recruiting

NCT05262803
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have had a specific type of heart attack (called a Type 1 MI) caused by a blood clot blocking a coronary artery, where blood test results showed elevated heart damage markers along with at least one other sign such as chest symptoms, abnormal heart tracing (ECG), new abnormal heart wave patterns, imaging showing new heart muscle damage, or a visible blood clot seen during a procedure to look at the arteries
  • People who have been treated for that heart attack with a procedure to open the blocked artery (called PCI) using a modern type of stent
  • People who score 25 or higher on a specific bleeding risk calculator called the PRECISE-DAPT score (confirm with trial site)
  • People aged 18 years or older

Who may not be able to join:

  • People who have allergies or medical reasons preventing them from taking aspirin or a class of blood-thinning medications called P2Y12 inhibitors
  • People who need to take blood-thinning medication in tablet form (oral anticoagulation) for another condition
  • People who have previously had a blood clot form inside a stent
  • People whose life expectancy is less than one year
  • People who required resuscitation after cardiac arrest and are in a severely reduced state of consciousness or require a breathing tube
  • People who have previously had bleeding inside the skull or brain
  • People who are actively bleeding at the time of enrolment (at a level defined as BARC 2 or higher — confirm with trial site)
  • Women who are pregnant, have given birth within the last 90 days, are breastfeeding, or are able to become pregnant and are not using contraception
  • People experiencing a severe spike in blood pressure (systolic above 180 mmHg and/or diastolic above 120 mmHg)
  • People who are unable to understand, follow, or comply with the study instructions and requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 35456851

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Rikke Sorensen
Registry
ClinicalTrials.gov
Start date
17 June 2022
Est. completion
1 December 2028

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

BARC type 2-5 bleedings; NACE (Net adverse clinical events)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov